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Table
Healthcare Costs during the 2-Year Study Period: CMV and No CMV Cohorts
Costs categories (2013 USD) CMV
cohort
(N ¼113)
No CMV
cohort
(N ¼ 113)
Cost
difference
P-value
Total costs 586,416.0 305,462.1 280,953.9 <.0001
Medical costs 543,813.1 276,593.3 267,219.7 <.0001
Inpatient services costs 343,691.6 157,995.6 185,696.0 <.0001
Emergency room
services costs
4,555.3 5,404.2 -848.9 0.2860
Outpatient services costs 195,566.2 113,193.6 82,372.6 <.0001
Drug costs 42,602.9 28,868.7 13,734.2 0.0079
Subcategories of total costs
Antiviral drug costs 6,920.6 449.7 6,470.9 <.0001
CMV laboratory test costs 3,357.1 1,473.3 1,883.7 0.0002
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suppresses T lymphocyte activity, and is used for GVHD
prophylaxis. According to some reports, pre-engraftment
immune reactions (PIR) occur early after CBT. During PIR
phase, we often experience instability of blood concentration
of TAC, and need the dose of the drug adjusted accordingly.
There are no reports assessing changes in TAC concentration
during the PIR phase.
Patients and Methods: Between July 2003 and November
2013, 105 patients received single-unit cord blood trans-
plantation (CBT) at our institution. We analyzed data for 63
patients for whom only TAC was used for GVHD prophylaxis.
The conditioning regimen was myeloablative conditioning
regimen for 11 patients and reduced intensity conditioning
for 52 patients. We assumed that the blood concentration of
TAC would reach a steady state between days 5 to 7 and
would be proportional to the dose used. Thus, the average
concentration of days 5 to 7 was used as the reference value.
TAC dose was adjusted based on blood concentration and
patient body weight, and compared with the reference dose
until day 40. PIR was diagnosed based on the criteria set forth
by Wake et al.
Results: Engraftment was achieved in 59 patients (median,
day 25), and 46 developed PIR. The blood concentration of
TAC signiﬁcantly decreased in the PIR group on day 8 (P<
0.001), but not in non-PIR group. On days 8, 9, and 10, the
adjusted dose of TAC signiﬁcantly increased in the PIR group
(P<0.001, 0.001, and 0.003, respectively) corresponding to
the decreased blood concentration of TAC, but not in the non-
PIR group.
Conclusions: Decreased blood concentration of TAC and
increased requirement of TAC dose in the PIR phase were
observed. During the PIR phase, frequent check of the TAC
blood concentration and adjustment of the drug should be
performed. These phenomena are possibly associated with T
lymphocyte activation.423
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Background: Cytomegalovirus (CMV), a common opportu-
nistic infection among stem cell transplant recipients, is
associated with substantial morbidity and mortality. Limited
information is available regarding the economic conse-
quences of CMV disease among these patients. The current
study evaluated the incremental healthcare costs associated
with CMV disease among stem cell transplant recipients.
Methods: Adults with stem cell transplant were identiﬁed in
the Truven Health MarketScan database (Q1 2002-Q4
2011). Patients were required to have 2 years of continuous
enrollment following the transplantation. They were classi-
ﬁed into the CMV cohort if they had  1 observed CMV
diagnosis within the 2-year period after transplantation
(study period), or the No CMV cohort if they did not have any
CMV diagnosis during the entire observation period in the
database. Patients in the CMV cohort were matched 1:1 to
patients in the No CMV cohort in two steps. The ﬁrst stepwas
exact matching based on age strata, gender, relevant
comorbidities, year of transplantation, type of stem cell
transplant, and donor type. The second stepwas a propensity
score match based on region of residence, health plan type,relevant comorbidities, and baseline healthcare resource
utilization and costs. The costs in the study period were
compared between the twomatched cohorts usingWilcoxon
signed-rank tests.
Results: Among 189 stem cell transplant recipients with
CMV and 2,539 recipients without CMV, a total of 113
matched pairs were identiﬁed. The baseline characteristics
were comparable between the matched CMV and No CMV
cohorts. During the 2-year study period, the CMV cohort was
associated with signiﬁcantly higher costs across all cost
categories. The total costs were $586,416 in the CMV cohort
vs. $305,462 in the No CMV cohort (incremental cost of
$280,954, p < 0.0001). The majority of the differences were
attributable to the incremental medical costs, accounting for
w95% of the total incremental costs (Table).
Conclusions: Stem cell transplant recipients with CMV dis-
ease incurred signiﬁcantly higher healthcare costs, including
costs for CMV lab tests and antiviral drugs, than those
without CMV disease.424
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Introduction: Cytomegalovirus (CMV) causes signiﬁcant
morbidity and mortality after allogeneic hematopoietic stem
cell transplant (allo-HSCT). Factors associated with progres-
sion from CMV viremia to disease despite pre-emptive CMV
treatment are poorly deﬁned. We sought to identify risk
factors among adult allo-HSCT recipients.
Methods: Retrospective single-center case-control study.
The McGill University Health Centre SCT Program database
was used to identify adults receiving a ﬁrst allo-HSCT be-
tween January 1, 2006 and February 12, 2013, and who
experienced 1 episode of CMV viremia detected by poly-
merase chain reaction (PCR). Medical records of cases (CMV
disease) and controls (without disease) were reviewed for
the following data: characteristics of recipient, donor, stem
cell graft, transplant procedure, viremic episodes, steroid use
post-transplant, and occurrence of acute and/or chronic
GVHD post-transplant. For analysis, Fisher’s exact test or
Wilcoxon Rank Sum test (for categorical and continuous
variables, respectively) was used. Variables were selected for
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regression analysis.
Results: Of 134 allo-HSCTs, 29 (21.6%) patients experienced
CMV viremia. Among these patients, median age was 51
years (range 27-67), with 48 episodes of viremia. Nine (31%)
viremic patients developed CMV disease.
CMV disease occurred at a median of 124 days post HSCT
(range 61-322). Patients with CMV disease had a median of 2
viremic episodes before disease (range 1-4). Disease
occurred at a median of 33 days from the start of the last
viremic episode, and 75 days from the start of the ﬁrst
episode of viremia.
On univariate analysis, factors associated with progres-
sion to CMV disease were: steroid-refractory acute GVHD (60
vs. 20%, p¼0.028); number of episodes of viremia >1x103
copies/mL (mean 2.4 vs 1.1, p¼0.016); longer duration of
viremia (mean 38 vs. 22 days, p¼0.01); higher peak viral load
(mean 4.49x105 vs. 8.31x103 copies/mL, p<0.001); and fail-
ure of pre-emptive ganciclovir therapy (50 vs. 10%, p¼0.015).
On multivariate analysis, no factors were signiﬁcantly asso-
ciated with progression to CMV disease.
CMV-related mortality was 33%. All-cause mortality was
signiﬁcantly higher in patients developing CMV disease (100
vs. 35%, log rank test p¼0.0027).
Conclusions: In adult allo-HSCT recipients experiencing 1
episode of CMV viremia, we found by univariate analysis that
patients who developed CMV disease were more likely to
have steroid refractory acute GVHD, more episodes of
viremia >1x103 copies/mL, a longer duration of viremia, and
to have failed ﬁrst-line pre-emptive ganciclovir therapy. This
study, while limited, suggests that these risk factors may be
predictive of CMV disease. Larger, prospective studies are
needed to conﬁrm these risk factors, some of which may be
amenable to more aggressive anti-viral therapy.425
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Introduction: Haplo-HCT is used increasingly as a treatment
for patients with hematologic disorders lacking suitable HLA
matched donors. Graft failure or rejection after myelo-
ablative conditioning (MAC) carries high mortality. We
present case of a patient with graft rejection post haplo-HCT
salvaged with second haplo-HCT using second related
donor.
Case Report: A 28 year old male presented with 3 week his-
tory of progressive weakness. He was severely pancytopenic
withWBC of 2.4, Hb of 4g/dl and platelet count of 14k. Work-
up for secondary causes of pancytopenia was negative.
Complete blood count performed a year earlier was normal.
Bone marrow was 70% cellular with dyserythropoiesis,
decreased megakaryocytes and normal myeloid precursors.
Marrow cytogenetics and Fluorescent in-situ Hybridization
panel for myelodysplastic syndrome was normal. Peripheral
blood ﬂow cytometry for paroxysmal nocturnal hemoglo-
binuria showed a small CD59 deﬁcient red cell clone (1.9%).His cytopenias progressed on high dose steroids. Repeat
marrow 4 weeks later was similar to his original marrow.
Patient had no suitable HLA matched related or unrelated
donor. He underwent Tcell replete peripheral blood stem cell
transplantation (PBSCT) from his haplomatched sister
following MAC with ﬂudarabine (FLU), busulfan and cyclo-
phosphamide (CY) with post transplant CY (PTC) and graft
versus host disease (GVHD) prophylaxis withmycophenolate
mofetil (MMF) and tacrolimus. Cell dose was CD34/kg 5 x 106
and CD3/kg 4.76 x 1010. Pretransplant screening for donor
speciﬁc antibodies (DSA) was negative. Four weeks after
transplant, patient remained severely pancytopenic. Bone
marrow exam showed an acellular marrow and peripheral
chimerism studies were fully recipient. Repeat screening for
DSA was again negative. Patient underwent a second T cell
replete PBSCTon day 39 using his haplomatched father as the
donor. The identical haplotype of the father was different
from his original donor. Patient underwent reduced intensity
conditioningwith FLU, CYand TBI 200 cGywith standard PTC
andGVHDprophylaxiswithMMFand tacrolimus. Post second
transplant, patient neutrophil and platelet engrafted on day
19andday32 respectively. Chimerismpost secondhaplo-HCT
was fully donor. During hospital course patient had multiple
complications. He developed fungemia (Debaryomyces spe-
cies) on day 24 postﬁrst transplant. Post second transplant he
developed oliguric renal failure requiring transient hemodi-
alysis and liver function test (LFT) abnormalities with peak
bilirubin of 12.1mg/dl. Liver biopsy showed drug induced
toxicity. Both his renal function and his LFT have since
improved and are near normal.
Conclusion: Graft rejection in a patient undergoing hap-
loidentical transplant could be successfully salvaged with a
second transplant using a different haploidentical donor and
with reduced intensity conditioning.426
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Background: VTE is a potentially life threatening condition
that requires early recognition and treatment. An increased
incidence of VTE with sirolimus-based immunosuppressive
regimen has been reported in solid organ transplant. Limited
data exist on VTE incidence in allo-HCT with sirolimus-based
GVHD prophylaxis.
Materials and Methods: We analyzed 892 consecutive allo-
HCT recipients between 1/1/2008 and 12/31/2013 at Mofﬁtt
Cancer Center. Baseline characteristics and VTE events were
collected. The association between VTE and baseline char-
acteristics including sirolimus and non-sirolimus GVHD
regimen was assessed using the Cox proportional hazard
model. The signiﬁcance level was set at  0.05. All analyses
were performed using Stata statistical analysis software
version 13.
